Angioimmunoblastic T-cell Lymphoma
📧 Sign up to get email alerts when something new happens for Angioimmunoblastic T-cell Lymphoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2019-05-31Clinical Trial Update: Study of MLN8237 in Participants With Advanced Hematological Malignancies [Phase 1]
Phase 1 study of MLN8237 in advanced hematological malignancies completed; results posted in 2019.
-
CLINICAL_TRIALS trial_result · 2018-06-25Clinical Trial Update: Combination Chemotherapy and Pralatrexate as First-Line Therapy in Treating Patients With Non-Hodgkin Lymphoma [Phase 2]
Phase 2 trial evaluating combination chemotherapy with pralatrexate as first-line therapy for non-Hodgkin lymphomas, including various T-cel…
-
CLINICAL_TRIALS trial_result · 2017-09-25Clinical Trial Update: Chidamide With PET Regimen for Angioimmunoblastic T Cell Lymphoma (PET: Prednisone, Etoposide and Thalidomide) [Phase 2]
Phase 2 trial evaluating chidamide in combination with a PET regimen (Prednisone, Etoposide, Thalidomide) for angioimmunoblastic T-cell lymp…
-
CLINICAL_TRIALS trial_result · 2017-06-29Clinical Trial Update: Gemcitabine Hydrochloride, Carboplatin, Dexamethasone, and Rituximab in Treating Patients With Previously Treated Lymphoid Malignancies [Phase 2]
A Phase 2 trial evaluating a combination of gemcitabine, carboplatin, dexamethasone, and rituximab in patients with previously treated lymph…
-
CLINICAL_TRIALS trial_result · 2017-05-25Clinical Trial Update: Vorinostat, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Lymphoma or Previously Untreated T-Cell Non-Hodgkin Lymphoma or Mantle Cell Lymphoma [Phase 1, Phase 2]
A Phase 1/2 trial evaluating a combination of vorinostat, rituximab, ifosfamide, carboplatin, and etoposide in adults with relapsed/refracto…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2017-05-08Clinical Trial Update: Oral Clofarabine for Relapsed/Refractory Non-Hodgkin Lymphoma [Phase 1, Phase 2]
Phase 1/2 trial of oral clofarabine in relapsed/refractory non-Hodgkin lymphoma completed with posted results.
-
CLINICAL_TRIALS trial_result · 2017-03-13Clinical Trial Update: A Phase II Study of Rituximab Combined With CHOP in T-cell Angio-immunoblastic Lymphoma [Phase 2]
This is a Phase II study evaluating Rituximab in combination with CHOP for untreated Angioimmunoblastic T-cell lymphoma. The trial status is…
-
CLINICAL_TRIALS trial_result · 2016-12-06Clinical Trial Update: CAR-pNK Cell Immunotherapy in CD7 Positive Leukemia and Lymphoma [Phase 1, Phase 2]
Phase 1/2 clinical trial update evaluating CAR-pNK cell immunotherapy for CD7-positive leukemias and lymphomas. The available snippet does n…
-
CLINICAL_TRIALS trial_result · 2016-03-10Clinical Trial Update: Alisertib in Treating Patients With Relapsed or Refractory Peripheral T-Cell Non-Hodgkin Lymphoma [Phase 2]
A Phase 2 trial sponsored by the National Cancer Institute evaluated alisertib for relapsed or refractory peripheral T-cell non-Hodgkin lymp…
-
CLINICAL_TRIALS trial_result · 2015-09-03Clinical Trial Update: Sorafenib Tosylate in Treating Patients With Recurrent Aggressive Non-Hodgkin's Lymphoma [Phase 2]
Phase 2 trial evaluating sorafenib tosylate in patients with recurrent aggressive non-Hodgkin lymphomas has completed, with results posted i…
-
CLINICAL_TRIALS trial_result · 2015-03-03Clinical Trial Update: RAD001 Combined With CHOP in Newly Diagnosed Peripheral T-cell Lymphomas [Phase 1, Phase 2]
A Phase 1/2 clinical trial evaluated everolimus (RAD001) in combination with CHOP chemotherapy for newly diagnosed peripheral T-cell lymphom…
-
CLINICAL_TRIALS trial_result · 2014-06-27Clinical Trial Update: Study of Bortezomib and Panobinostat in Treating Patients With Relapsed/Refractory Peripheral T-cell Lymphoma or NK/T-cell Lymphoma [Phase 2]
A completed Phase 2 study evaluating the combination of bortezomib and panobinostat in relapsed or refractory peripheral T-cell lymphomas an…
-
CLINICAL_TRIALS trial_result · 2014-02-24Clinical Trial Update: Oxaliplatin, Ifosfamide and Etoposide in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma [Phase 1]
Phase 1 study of oxaliplatin, ifosfamide, and etoposide in young patients with recurrent or refractory solid tumors or lymphomas; the trial …
-
CLINICAL_TRIALS trial_result · 2014-02-24Clinical Trial Update: Vorinostat in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphoma and Liver Dysfunction [Phase 1]
Phase 1 trial of vorinostat in adults with metastatic or unresectable solid tumors or lymphoma and liver dysfunction has completed.
-
CLINICAL_TRIALS trial_result · 2014-02-24Clinical Trial Update: Tanespimycin and Bortezomib in Treating Patients With Advanced Solid Tumors or Lymphomas [Phase 1]
Phase 1 trial evaluating the combination of tanespimycin and bortezomib in adults with advanced solid tumors or lymphomas; the study was ter…
-
CLINICAL_TRIALS trial_result · 2014-01-07Clinical Trial Update: FAU in Treating Patients With Advanced Solid Tumors or Lymphoma [Phase 1]
Phase 1 trial evaluating FAU in patients with advanced solid tumors or lymphoma has completed.
-
CLINICAL_TRIALS trial_result · 2013-12-03Clinical Trial Update: Bortezomib and Azacitidine in Treating Patients With Relapsed or Refractory T-Cell Lymphoma [Phase 1]
Phase 1 study evaluating the combination of bortezomib and azacitidine in adults with relapsed or refractory T-cell lymphomas; the trial is …
-
CLINICAL_TRIALS trial_result · 2013-09-30Clinical Trial Update: 3-AP and Gemcitabine in Treating Patients With Advanced Solid Tumors or Lymphoma [Phase 1]
Phase 1 trial evaluating Triapine (3-AP) in combination with gemcitabine in patients with advanced solid tumors or lymphoma has completed. I…
-
CLINICAL_TRIALS trial_result · 2013-08-26Clinical Trial Update: Fludarabine, Cyclophosphamide, and Thalidomide in Treating Patients With Angioimmunoblastic T-Cell Lymphoma [Phase 2]
This Phase 2 clinical trial evaluates a combination of fludarabine, cyclophosphamide, and thalidomide in treating patients with angioimmunob…
-
CLINICAL_TRIALS trial_result · 2013-06-04Clinical Trial Update: 17-N-Allylamino-17-Demethoxygeldanamycin and Bortezomib in Treating Patients With Relapsed or Refractory Hematologic Cancer [Phase 1]
Phase 1 clinical trial evaluating the combination of tanespimycin (17-allylamino-17-demethoxygeldanamycin) and bortezomib in relapsed or ref…
-
CLINICAL_TRIALS trial_result · 2013-02-08Clinical Trial Update: Cyclosporine in Treating Patients With Recurrent or Refractory Angioimmunoblastic T-Cell Lymphoma [Phase 2]
Phase 2 trial update on cyclosporine for recurrent or refractory angioimmunoblastic T-cell lymphoma; study terminated with results posted.
-
CLINICAL_TRIALS trial_result · 2013-01-25Clinical Trial Update: 17-DMAG in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphomas [Phase 1]
Phase 1 clinical trial evaluating 17-DMAG (alvespimycin), an HSP90 inhibitor, in patients with metastatic or unresectable solid tumors or ly…
-
CLINICAL_TRIALS trial_result · 2013-01-24Clinical Trial Update: Genetic Testing Plus Irinotecan in Treating Patients With Solid Tumors or Lymphoma [Phase 1]
A Phase 1 trial evaluating genetic testing-guided irinotecan therapy in patients with solid tumors or lymphoma; the study status is complete…
-
CLINICAL_TRIALS trial_result · 2013-01-23Clinical Trial Update: Oxaliplatin in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma [Phase 2]
A Phase 2 study evaluated oxaliplatin in patients with relapsed or refractory non-Hodgkin lymphoma across multiple subtypes and has complete…
-
CLINICAL_TRIALS trial_result · 2013-01-23Clinical Trial Update: 506U78 in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma or T-cell Lymphoma [Phase 2]
A Phase 2 trial investigating 506U78 in patients with recurrent or refractory non-Hodgkin's lymphoma and T-cell lymphomas was terminated.